menu
    • menu
    [{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Steba Biotech

    Menu

    Steba Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Steba Biotech

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Steba Biotech

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Steba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract ...

                            Details : The ENLIGHTED study aims to recruit 100 patients with low-grade UTUC in either the kidney or the ureter. The patients will be treated with Padeliporfin ImPACT in two phases, induction treatment and maintenance treatment, and will be followed up for 1-5 y...

                            Product Name : Padeliporfin ImPACT

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 20, 2021

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Steba Biotech

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Steba Biotech

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba Biotech

                            Details : This swiftly follows clearance of the Investigational New Drug (IND) application granted in December 2020 allowing initiation of the pivotal Phase 3 clinical trial of padeliporfin ImPACT in patients with low-grade UTUC, expected to begin enrollment in Q1...

                            Product Name : Padeliporfin ImPACT

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 15, 2021

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth